{"title":"Antifungal drugs","authors":"İlknur Akkuş, Birgül Kaçmaz","doi":"10.51271/jchor-0010","DOIUrl":null,"url":null,"abstract":"Fungal infections continue to emerge as an important cause of infectious disease and mortality in humans. Amphotericin B deoxycholate (ABD), was the first antifungal that was discovered, and it was released in 1958, and flucytosine, which was developed later and is effective against Candida and Cryptococcus, was introduced in 1978. The discovery of first-generation azoles (fluconazole and itraconazole) in the 1990s has created a new step in the treatment of fungi. In the years that followed, with the development of lipid formulations of amphotericin B, the introduction of second-generation azoles, and the release of the most recently developed class, echinocandins, the foundations of today’s existing antifungal classes were laid. This article is aimed to review the mechanism of action, side effects and clinical use indications of the main antifungal drugs used in the treatment of systemic fungal infections.","PeriodicalId":484721,"journal":{"name":"Journal of Current Hematology & Oncology Research","volume":"23 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Current Hematology & Oncology Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.51271/jchor-0010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Fungal infections continue to emerge as an important cause of infectious disease and mortality in humans. Amphotericin B deoxycholate (ABD), was the first antifungal that was discovered, and it was released in 1958, and flucytosine, which was developed later and is effective against Candida and Cryptococcus, was introduced in 1978. The discovery of first-generation azoles (fluconazole and itraconazole) in the 1990s has created a new step in the treatment of fungi. In the years that followed, with the development of lipid formulations of amphotericin B, the introduction of second-generation azoles, and the release of the most recently developed class, echinocandins, the foundations of today’s existing antifungal classes were laid. This article is aimed to review the mechanism of action, side effects and clinical use indications of the main antifungal drugs used in the treatment of systemic fungal infections.
真菌感染继续成为人类传染病和死亡的一个重要原因。两性霉素B脱氧胆酸酯(Amphotericin B deoxycholate, ABD)是最早发现的抗真菌药物,于1958年上市。氟胞嘧啶(flucytosine)是较晚开发的抗念珠菌和隐球菌的药物,于1978年上市。20世纪90年代发现的第一代唑类药物(氟康唑和伊曲康唑)在真菌治疗方面迈出了新的一步。在随后的几年里,随着两性霉素B脂质配方的发展,第二代唑类药物的引入,以及最近开发的棘白菌素类药物的发布,奠定了今天现有抗真菌类药物的基础。本文就目前治疗全身性真菌感染的主要抗真菌药物的作用机制、毒副作用及临床使用指征进行综述。